U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C3H7NO2S.ClH
Molecular Weight 157.619
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CYSTEINE HYDROCHLORIDE ANHYDROUS

SMILES

Cl.N[C@@H](CS)C(O)=O

InChI

InChIKey=IFQSXNOEEPCSLW-DKWTVANSSA-N
InChI=1S/C3H7NO2S.ClH/c4-2(1-7)3(5)6;/h2,7H,1,4H2,(H,5,6);1H/t2-;/m0./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C3H7NO2S
Molecular Weight 121.158
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68003545

Cysteine (cysteine hydrochloride is a salt) is a thiol-containing amino acid that is oxidized to form cystine. Cysteine is synthesized from methionine via the trans-sulfuration pathway in the adult, but newborn infants lack the enzyme, cystathionase, necessary to effect this conversion. Therefore, cysteine is generally considered to be an essential amino acid in infants.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
CYSTEINE HYDROCHLORIDE

Approved Use

Cysteine Hydrochloride Injection, USP 0.5 gram is indicated for use only after dilution as an additive to Aminosyn (a crystalline amino acid solution) to meet the intravenous amino acid nutritional requirements of infants receiving total parenteral nutrition.

Launch Date

5.30236801E11
Doses

Doses

DosePopulationAdverse events​
121 mg/kg 1 times / day multiple, intravenous (total daily dose)
Highest studied dose
Dose: 121 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 121 mg/kg, 1 times / day
Sources:
unhealthy, 34±6 weeks
n = 6
Health Status: unhealthy
Condition: Parenteral nutrition
Age Group: 34±6 weeks
Sex: M+F
Population Size: 6
Sources:
22 mg/g aminoacid 1 times / day multiple, intravenous (total daily dose)
Recommended
Dose: 22 mg/g aminoacid, 1 times / day
Route: intravenous
Route: multiple
Dose: 22 mg/g aminoacid, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Parenteral nutrition
Sources: Page: p.1
Disc. AE: Embolism pulmonary, Vein disorder NOS...
AEs leading to
discontinuation/dose reduction:
Embolism pulmonary
Vein disorder NOS
Thrombosis
Blood urea nitrogen increased
Acid base balance abnormal
Hyperammonemia
Aluminium abnormal NOS
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Acid base balance abnormal Disc. AE
22 mg/g aminoacid 1 times / day multiple, intravenous (total daily dose)
Recommended
Dose: 22 mg/g aminoacid, 1 times / day
Route: intravenous
Route: multiple
Dose: 22 mg/g aminoacid, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Parenteral nutrition
Sources: Page: p.1
Aluminium abnormal NOS Disc. AE
22 mg/g aminoacid 1 times / day multiple, intravenous (total daily dose)
Recommended
Dose: 22 mg/g aminoacid, 1 times / day
Route: intravenous
Route: multiple
Dose: 22 mg/g aminoacid, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Parenteral nutrition
Sources: Page: p.1
Blood urea nitrogen increased Disc. AE
22 mg/g aminoacid 1 times / day multiple, intravenous (total daily dose)
Recommended
Dose: 22 mg/g aminoacid, 1 times / day
Route: intravenous
Route: multiple
Dose: 22 mg/g aminoacid, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Parenteral nutrition
Sources: Page: p.1
Embolism pulmonary Disc. AE
22 mg/g aminoacid 1 times / day multiple, intravenous (total daily dose)
Recommended
Dose: 22 mg/g aminoacid, 1 times / day
Route: intravenous
Route: multiple
Dose: 22 mg/g aminoacid, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Parenteral nutrition
Sources: Page: p.1
Hyperammonemia Disc. AE
22 mg/g aminoacid 1 times / day multiple, intravenous (total daily dose)
Recommended
Dose: 22 mg/g aminoacid, 1 times / day
Route: intravenous
Route: multiple
Dose: 22 mg/g aminoacid, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Parenteral nutrition
Sources: Page: p.1
Thrombosis Disc. AE
22 mg/g aminoacid 1 times / day multiple, intravenous (total daily dose)
Recommended
Dose: 22 mg/g aminoacid, 1 times / day
Route: intravenous
Route: multiple
Dose: 22 mg/g aminoacid, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Parenteral nutrition
Sources: Page: p.1
Vein disorder NOS Disc. AE
22 mg/g aminoacid 1 times / day multiple, intravenous (total daily dose)
Recommended
Dose: 22 mg/g aminoacid, 1 times / day
Route: intravenous
Route: multiple
Dose: 22 mg/g aminoacid, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Parenteral nutrition
Sources: Page: p.1
PubMed

PubMed

TitleDatePubMed
Mechanisms of inhibitory effects of zinc and cadmium ions on agonist binding to adenosine A1 receptors in rat brain.
1999 Aug 15
The effect of cysteine on the altered expression of class alpha and mu glutathione S-transferase genes in the rat liver during protein-calorie malnutrition.
2000 Oct 18
Purification of 20S proteasomes.
2001
The neuroprotective effects of phytoestrogens on amyloid beta protein-induced toxicity are mediated by abrogating the activation of caspase cascade in rat cortical neurons.
2001 Feb 16
The extracellular calcium-sensing receptor dimerizes through multiple types of intermolecular interactions.
2001 Feb 16
Molecular mechanism of hypoxia-inducible factor 1alpha -p300 interaction. A leucine-rich interface regulated by a single cysteine.
2001 Feb 2
Ligand-independent dimerization and activation of the oncogenic Xmrk receptor by two mutations in the extracellular domain.
2001 Feb 2
Determination of disulfide bond assignments and N-glycosylation sites of the human gastrointestinal carcinoma antigen GA733-2 (CO17-1A, EGP, KS1-4, KSA, and Ep-CAM).
2001 Feb 23
Degradation of nucleosome-associated centromeric histone H3-like protein CENP-A induced by herpes simplex virus type 1 protein ICP0.
2001 Feb 23
Expression of gamma-glutamyl transpeptidase protects ramos B cells from oxidation-induced cell death.
2001 Feb 9
Newly synthesized human delta opioid receptors retained in the endoplasmic reticulum are retrotranslocated to the cytosol, deglycosylated, ubiquitinated, and degraded by the proteasome.
2001 Feb 9
Metabolism of [(14)C]omapatrilat, a sulfhydryl-containing vasopeptidase inhibitor in humans.
2001 Jan
Regulation of proteolysis.
2001 Jan
Protein metabolism at the crossroads?
2001 Jan
Role of aminothiols as a component of the plasma antioxidant system and relevance to homocysteine-mediated vascular disease.
2001 Jan
Retinoids as ligands and coactivators of protein kinase C alpha.
2001 Jan
Epithelial sodium channel pore region. structure and role in gating.
2001 Jan 12
The human homolog of Saccharomyces cerevisiae Apg7p is a Protein-activating enzyme for multiple substrates including human Apg12p, GATE-16, GABARAP, and MAP-LC3.
2001 Jan 19
A proposed common structure of substrates bound to mitochondrial processing peptidase.
2001 Jan 19
Structural requirements for the stabilization of metarhodopsin II by the C terminus of the alpha subunit of transducin.
2001 Jan 26
The proteasome regulates receptor-mediated endocytosis of interleukin-2.
2001 Jan 5
Identification of a membrane-associated cysteine protease with possible dual roles in the endoplasmic reticulum and protein storage vacuole.
2001 Jan 5
Activation of the cyclin-dependent kinase CTDK-I requires the heterodimerization of two unstable subunits.
2001 Mar 16
Functional rescue of the nephrogenic diabetes insipidus-causing vasopressin V2 receptor mutants G185C and R202C by a second site suppressor mutation.
2001 Mar 16
A proteome analysis of the cadmium response in Saccharomyces cerevisiae.
2001 Mar 16
The transport activity of the Na+-Ca2+ exchanger NCX1 expressed in HEK 293 cells is sensitive to covalent modification of intracellular cysteine residues by sulfhydryl reagents.
2001 Mar 23
The cytosolic O-acetylserine(thiol)lyase gene is regulated by heavy metals and can function in cadmium tolerance.
2001 Mar 23
Agonist-induced conformational changes at the cytoplasmic side of transmembrane segment 6 in the beta 2 adrenergic receptor mapped by site-selective fluorescent labeling.
2001 Mar 23
Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.
2001 Mar 23
Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagulant by inhibiting intrinsic tenase and prothrombinase.
2001 Mar 30
The structure of the C4C4 ring finger of human NOT4 reveals features distinct from those of C3HC4 RING fingers.
2001 Mar 30
Amino acid residues in the PSI domain and cysteine-rich repeats of the integrin beta2 subunit that restrain activation of the integrin alpha(X)beta(2).
2001 Mar 9
Redox properties and coordination structure of the heme in the co-sensing transcriptional activator CooA.
2001 Mar 9
The putative glutathione peroxidase gene of Plasmodium falciparum codes for a thioredoxin peroxidase.
2001 Mar 9
Rare somatic p53 mutation identified in breast cancer: a case report.
2001 Mar-Apr
Expression-independent consumption of substrates in cell-free expression system from Escherichia coli.
2001 Nov 17
Patents

Sample Use Guides

Cysteine Hydrochloride Injection, USP 0.5 gram is intended for use only after dilution in Aminosyn (a crystalline amino acid solution). Each 10 mL of Cysteine Hydrochloride Injection, USP 0.5 gram should be combined aseptically with 12.5 grams of amino acids, such as that present in 250 mL of Aminosyn 5%. The admixture is then diluted with 250 mL of dextrose 50% or such lesser volume as indicated. Equal volumes of Aminosyn 5% and dextrose 50% produce a final solution which contains Aminosyn 2.5% in dextrose 25%, which is suitable for administration by central venous infusion. Administration of the final admixture should begin within one hour of mixing due to the oxidative degradation of cysteine in the higher pH environment of the amino acid and dextrose admixture. Otherwise, the admixture should be refrigerated immediately and used within 12 hours of the time of mixing.
Route of Administration: Intravenous
N-acetyl-L-cysteine (NAC) (1 µM ~ 1 mM) and cysteine (10 µM ~ 1 mM) increased [Ca(2+)]i in human neutrophils in a concentration-dependent manner. In Ca(2+)-free buffer, NAC- and cysteine-induced [Ca(2+)]i increase in human neutrophils completely disappeared, suggesting that NAC- and cysteine-mediated increase in [Ca(2+)]i in human neutrophils occur through Ca(2+) influx. NAC- and cysteine-induced [Ca(2+)]i increase was effectively inhibited by calcium channel inhibitors SKF96365 (10 µM) and ruthenium red (20 µM). In Na(+)-free HEPES, both NAC and cysteine induced a marked increase in [Ca(2+)]i in human neutrophils, arguing against the possibility that Na(+)-dependent intracellular uptake of NAC and cysteine is necessary for their [Ca(2+)]i increasing activity. The results show that NAC and cysteine induce [Ca(2+)]i increase through Ca(2+) influx in human neutrophils via SKF96365- and ruthenium red-dependent way.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:48:10 UTC 2023
Edited
by admin
on Fri Dec 15 15:48:10 UTC 2023
Record UNII
A9U1687S1S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CYSTEINE HYDROCHLORIDE ANHYDROUS
II   MI  
Common Name English
L-CYSTEINE HCL
Common Name English
CYSTEINE, L-, HYDROCHLORIDE
Systematic Name English
Cysteine hydrochloride [WHO-DD]
Common Name English
L-CYSTEINE, HYDROCHLORIDE (1:1)
Systematic Name English
CYSTEINE HYDROCHLORIDE, ANHYDROUS
Common Name English
CYSTEINE HYDROCHLORIDE ANHYDROUS [II]
Common Name English
CYSTEINE HYDROCHLORIDE ANHYDROUS [MI]
Common Name English
L-CYSTEINE HYDROCHLORIDE [USP-RS]
Common Name English
L-CYSTEINE HYDROCHLORIDE
Systematic Name English
Code System Code Type Description
RS_ITEM_NUM
1161509
Created by admin on Fri Dec 15 15:48:10 UTC 2023 , Edited by admin on Fri Dec 15 15:48:10 UTC 2023
PRIMARY
NCI_THESAURUS
C1505
Created by admin on Fri Dec 15 15:48:10 UTC 2023 , Edited by admin on Fri Dec 15 15:48:10 UTC 2023
CONCEPT Dietary Supplement
SMS_ID
100000085406
Created by admin on Fri Dec 15 15:48:10 UTC 2023 , Edited by admin on Fri Dec 15 15:48:10 UTC 2023
PRIMARY
FDA UNII
A9U1687S1S
Created by admin on Fri Dec 15 15:48:10 UTC 2023 , Edited by admin on Fri Dec 15 15:48:10 UTC 2023
PRIMARY
NCI_THESAURUS
C77372
Created by admin on Fri Dec 15 15:48:10 UTC 2023 , Edited by admin on Fri Dec 15 15:48:10 UTC 2023
PRIMARY
CAS
52-89-1
Created by admin on Fri Dec 15 15:48:10 UTC 2023 , Edited by admin on Fri Dec 15 15:48:10 UTC 2023
PRIMARY
EVMPD
SUB12522MIG
Created by admin on Fri Dec 15 15:48:10 UTC 2023 , Edited by admin on Fri Dec 15 15:48:10 UTC 2023
PRIMARY
PUBCHEM
60960
Created by admin on Fri Dec 15 15:48:10 UTC 2023 , Edited by admin on Fri Dec 15 15:48:10 UTC 2023
PRIMARY
EPA CompTox
DTXSID0020367
Created by admin on Fri Dec 15 15:48:10 UTC 2023 , Edited by admin on Fri Dec 15 15:48:10 UTC 2023
PRIMARY
ECHA (EC/EINECS)
200-157-7
Created by admin on Fri Dec 15 15:48:10 UTC 2023 , Edited by admin on Fri Dec 15 15:48:10 UTC 2023
PRIMARY
Related Record Type Details
SOLVATE->ANHYDROUS
PARENT -> SALT/SOLVATE
Related Record Type Details
PARENT -> IMPURITY
Related Record Type Details
ACTIVE MOIETY